The 2021 WHO classification considers the homozygous deletion of CDKN2A/B as a molecular feature of grade 4 in IDH-mutant astrocytomas and also as a molecular feature of grade 3 oligodendroglioma (5). Here, CDKN2A is linked to astrocytoma (excluding glioblastoma).